Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Metastatic squamous neck cancer with occult primary
Stage/Subtype:  untreated metastatic squamous neck cancer with occult primary
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 31 for your search:
Start Over
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
Stereotactic Radiosurgery in Treating Patients with Oligometastatic Disease
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-027, NCI-2014-01952, REN13120042, UPCI #10-027, NCT01345539
Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-028, NCI-2014-01953, REN13120040, UPCI# 10-028, NCT01345552
Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LOXO-TRK-15002, NCI-2015-01947, NCT02576431
Nivolumab with Image Guided, Stereotactic Body Radiation Therapy or Nivolumab Alone in Treating Patients with Metastatic Head and Neck Squamous Cell Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-253, NCI-2016-00261, NCT02684253
Axitinib in Treating Patients with Recurrent or Metastatic Head and Neck Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2016.040, NCI-2016-01064, NCT02762513
Dose-escalation Study of Oral CX-4945
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C4-08-001, NCI-2009-01571, NCT00891280
Everolimus, Cisplatin, and Radiation Therapy in Treating Patients with Locally Advanced Head and Neck Squamous Cell Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 09-342, NCI-2010-00294, NCT01058408
Romidepsin in Treating Patients with Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors with Liver Dysfunction
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9008, NCI-2012-01040, CDR0000737061, J11105, NA_00052587, NCI-2013-01545, NCT01638533
Buparlisib, Cisplatin and Radiation Therapy in Treating Patients with Stage III/IV Head and Neck Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-008, NCI-2014-02351, NCT02113878
Ficlatuzumab and Cetuximab in Treating Patients with Recurrent or Metastatic Head and Neck Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-059, NCI-2015-00056, UPCI #13-059, NCT02277197
Cetuximab, BYL719, and Intensity-Modulated Radiation Therapy in Treating Patients with Stage III-IVB Head and Neck Squamous Cell Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-116, NCI-2014-02290, NCT02282371
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B0601002, NCI-2015-00761, 2014-004107-75, NCT02315066
Ceritinib and Everolimus in Treating Patients with Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0890, NCI-2015-00062, NCT02321501
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: M14-429, NCI-2015-00519, 2014-003557-34, NCT02365662
PCA062 in pCAD-positive Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CPCA062X2101, NCI-2015-00491, 2014-003732-40, NCT02375958
Stereotactic Body Radiation Therapy in Treating Patients with High Risk Locally Advanced Head and Neck Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE 8314, NCI-2014-02279, NCT02388932
A Study of Subcutaneous Recombinant Human hetIL-15 (IL15/sIL-15Ra) in Adults With Metastatic Cancers
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AT-ONC-101, NCI-2015-00991, CRADA #02949, NCT02452268
WEE1 inhibitor MK-1775, Docetaxel, and Cisplatin before Surgery in Treating Patients with Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9168, NCI-2015-01064, NCT02508246
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CP-MGA271-03, NCI-2015-01495, NCT02475213
Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PM60184-A-003-14, NCI-2015-01510, 2014-002943-16, NCT02533674
Phase 1 Combination Study of MM-151 and MM-121
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MM-151-01-01-02, NCI-2015-01527, NCT02538627
Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: FPA008-003, NCI-2015-01622, NCT02526017
VX-970, Cisplatin, and Radiation Therapy in Treating Patients with Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9950, NCI-2015-01643, NCT02567422
Start Over